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more research and more discussion on deﬁning endocrine disrupting
properties and then regulating potentially endocrine active sub-
stances. The November 2009 workshop in Brussels was the ﬁrst in a
series to be organised by the SAFE consortiumwith the aim of bringing
scientiﬁc clarity to this discussion.
The paper that follows expresses solely the opinions and
recollections of the author. Each expert presentation summarised
below was offered to the presenter for review and comment; those
presentations with an * next to the author's name were indeed
reviewed and approved by the presenter. Nonetheless, the paper does1. Executive summary
On 26 and 27 November 2009, 29 experts met in Brussels to
discuss current opinions on the effects of dietary exposure to
endocrine-active pesticide residues. Representatives from academia,
industry, government and non-proﬁt organisations participated in a
workshop combining expert lectures and breakout sessions.
The workshop was organised such that 8 presentations by experts
with specialties in different aspects of endocrine disruption were
followed by a breakout group session. Each of the 4 breakout groups
discussed 2 questions posed to them by the workshop organisers and
then gave a short presentation on their responses to the questions,
including whether or not they reached consensus on those responses.
In the pages that follow, the 8 expert presentations and the
presentations from the breakout sessions are summarised in detail.
Interestingly, only one of the breakout groups was able to say that
they had no signiﬁcant disagreements, and for 3 of the questions 2
groups indicated that they could not reach any signiﬁcant agreement
at all (‘Is endocrine disruption a mechanism essentially different from
other toxicological mechanisms?’, ‘Should [endocrine disrupting
chemicals] therefore be regulated using different criteria?’ and ‘Is
the effort currently dedicated to this subject [of pesticides with
potentially endocrine disrupting properties] proportional to the real
health risk?’). In each of these cases, the reason for the lack of
consensus was attributed to a lack of adequate knowledge: Either on
how to measure endocrine effects or on what the real health risks ofBrussels, Belgium. Tel.: +32 2
.
-ND license.these effects might be. These responses clearly underline the need for
not express the opinions of the presenters, the Workshop organiser –
the SAFE consortium, the Workshop co-sponsor – BASF, nor of any of
the Workshop attendees. Sole responsibility for the content lies with
the author of the paper.
2. Introduction
The endocrine system is, along with the nervous system, an
‘integrating’ system i.e., endocrine products, or hormones, regulate the
function of other systems in the body. This capacity of hormones to
inﬂuence many aspects of an organism's growth, development and
homeostasis is perhaps a reason so much attention has recently been
given to potentially endocrine disrupting substances in the environ-
ment, and why emotions tend to run high in this discussion. (For a
short non-expert review on the form and function of the endocrine
system see Section 6, Appendix.)
New pesticide regulations were recently introduced by the
European Parliament and they contain, for the ﬁrst time, speciﬁc
reference to endocrine disrupting properties. On 21 October 2009,
regulation (EC) No 1107/2009 replaced Council Directive 91/414/EEC.
Annex II, Article 3.6.5 of the new pesticide regulation concerns human
health and endocrine-active pesticides and it states,
Anactive substance, safener or synergist shall only be approved if, on the
basis of the assessment of Community…, it is not considered to have
endocrine disrupting properties that may cause adverse effects in
humans, unless the exposure of humans to that active substance, safener
or synergist in a plant protection product, under realistic proposed
conditions of use, is negligible that is, the product is used in closed
systems or in other conditions excluding contact with humans and
where residues of the active substance, safener or synergist concerned
on food and feed do not exceed the default value set in accordance with
point (b) of Article 18(1) of Regulation (EC) No 396/2005.
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Fig. 1. a) The normal interaction between a hormone, estrogen or thyroid hormone, and
it's nuclear receptor (ER or TR), both of which interact with receptor cofactors. The
hormone receptor element (HRE), made up of the hormone bound to the receptor and
any associated co-factors, can then modify gene transcription. b) The presence of
hormone mimics results in competition for binding at the hormone receptor. Binding of
the endocrine disrupter may either activate or block the HRE, in either case altering
normal gene transcription.
981K. Flynn / Environment International 37 (2011) 980–990Article 3.8.2 of Annex II concerns ecotoxicology and the statement
is the same as above except that ‘effects in humans’ is replaced by
‘effects in non-target organisms’.
It is clear that substances with endocrine disrupting properties are
to be avoided; however there is not a clear consensus on how to
identify and evaluate endocrine disrupting properties and no
guidance yet provided in the new European Regulation. By 14
December 2013, a draft of the speciﬁc scientiﬁc criteria for the
determination of endocrine disrupting properties is to be presented
by the European Commission to the Standing Committee on the Food
Chain and Animal Health. As stated in the Regulation,
Within four years from the entry into force of this Regulation, the
Commission shall present to the Committee referred to in Article 79
(1) a draft of the measures concerning speciﬁc scientiﬁc criteria for
the determination of endocrine disrupting properties to be adopted in
accordance with the regulatory procedure with scrutiny referred to
in Article 79 (4).
Thus, the Commission is currently gathering facts and preparing
opinions on the speciﬁc scientiﬁc criteria which will be used in
deﬁning endocrine disrupting properties of pesticide products. This
workshop was organized so that experts from different sectors
(academia, industry, government, non-proﬁt) could discuss their
understanding of what makes an endocrine-active substance an
endocrine disrupter. A goal of the workshop was to stimulate an
informed debate in which scientiﬁc results could be presented,
interpreted and discussed relevant to their application in legislation.
3. Expert presentations
The Science of Endocrine Disrupters and Relevance to Human
Health.
Dr. Jan-Åke Gustafsson*, Karolinska Institute, Sweden.
This presentation deﬁned hormones as signaling molecules that
communicate with cells throughout the body. Hormones are respon-
sible for homeostasis and are also particularly important during
embryonic development, puberty and reproduction. Hormones act by
binding to hormone receptors located in the nucleus of their target
cells (for thyroid hormone and sex steroids). This hormone-receptor
complex then regulates the transcription of genes (Fig. 1a).
Endocrine disrupters may interfere with the functioning of
hormonal systems in at least three possible ways: 1) By mimicking
the action of a naturally-produced hormone, producing similar but
exaggerated chemical reactions in the body (Fig. 1b); 2) By blocking
hormone receptors, preventing or diminishing the action of normal
hormones (Fig. 1b) and 3) By affecting the synthesis, transport,
metabolism and/or excretion of hormones, thus altering the concen-
trations of natural hormones. In some species of wildlife and in
laboratory animals, endocrine disrupters have been reported to have
harmful effects on reproduction, growth and development.
In humans, increases in some diseases and disorders may be
related to disturbance of the endocrine system. There are many
disorders of the foetal, pubertal and adult reproductive system, in
both males and females, which are believed to involve endocrine
disruption in their pathogenesis (Diamanti-Kandarakis et al., 2009).
Two of these, breast cancer and testicular cancer, have increased
dramatically: an 81% rise in breast cancer between 1971 and 1991 in
the UK and a 46% rise in testicular cancer between 1995 and 2006 in
the US state of Texas for example. In both of these groups, the largest
increases in cancer incidence were not in the oldest age brackets, as
would be expected if longer life spans led to more cancer, but instead
in the 55–64 and 20–50 year old groups, respectively. It is possible
that these increases are due, at least in part, to the increase in
endocrine-active chemicals in the environment. Support for the idea
that chemical exposure is linked to testicular cancer comes from astudy in Northern Europe showing that Denmark has a higher
incidence of testicular cancer than Finland. In Denmark, breast milk
(as a measurement of infant chemical exposure) also contains higher
amounts of dioxins, PCBs and some pesticides (hexachlorobenzene
and dieldrin) than in Finland (Krysiak-Baltyn et al., 2009).
The CASCADE Network of Excellence was funded by the European
Commission beginning in 2004 with a mission to integrate European
research, teaching, risk assessment and dissemination of results about
endocrine disrupting contaminants in food. The CASCADE test
platform to assess endocrine disruption included computer and test
tube models, biomarkers and cell and animal models to assess effects
on animal and human health so that effective risk assessment could be
performed. In order to predict toxicity, results frommultiple methods
(in silico, in vitro, in vivo) are needed. (See the CASCADE website,
http://www.cascadenet.org, for more information.)
One model substance studied in CASCADE is bisphenol A (BPA),
used in the production of many food-related items including baby
bottles, plastic food containers and tableware, etc. and released from
these products into food and drinks. In numerous CASCADE studies,
results from different in vivo and in vitro models collectively indicate
that themechanismswhereby BPA interferes with hormone signalling
are both diverse and complex. Additionally, the range of pathways
with which BPA potentially interferes may be much wider than
982 K. Flynn / Environment International 37 (2011) 980–990expected, and many may therefore be overlooked if toxicity is
measured by the classical testing paradigm only (e.g. the Uterotrophic
or Hershberger assays). Based on these knowledge gaps, CASCADE
believes that it is too early to conclude that harmful effects of BPA on,
for example, foetal development can be ruled out. Instead, the
developing foetus may be particularly vulnerable to BPA, and perhaps
also to other endocrine active substances, at speciﬁc windows of time
(Bondesson et al. 2009).
Assessing and Mitigating Endocrine Risks Associated with
Pesticides.
Dr. Ivana Fegert*, BASF, Germany.
The presentation began with a review of the new pesticide
legislation (see Introduction, above). Several similar deﬁnitions of
endocrine disruption have been proposed since research in this area
began in earnest in the 1990s. TheWeybridge deﬁnition of 1996 is the
one chosen by the European Centre for Ecotoxicology and Toxicology
of Chemicals (ECETOC).
An endocrine disrupter is an exogenous substance that causes
adverse health effects in an intact organism, or its progeny,
secondary (or consequent) to changes in endocrine function.
Currently both targeted endpoint and multi-endpoint studies are
used as standard test methods to detect endocrine disrupting activity.
The targeted endpoint studies include both in vitro and in vivo screens
and assays and those used to test for human health effects are
summarised below:in vitro screens/assays in vivo screens/assaysEstrogen receptor binding (in rat uterus) Uterotrophic (rat)
Androgen receptor binding (in rat prostate) Hershberger (rat)
Steroidogenesis (in human cell line H295R) Pubertal female (rat)
Aromatase (human recombinant) Pubertal male (rat)Additionally, an amphibian metamorphosis test in the frog and a
ﬁsh short term reproduction test are currently used in vivo screens for
potential ecotoxicological effects of endocrine disruptors.
Multi-endpoint studies are currently in use to test for mammalian
toxicity; all are performed in the rat and include the following:
1 and 2 generation studies
Reproductive screening test
Combined 28 day/reproduction screening
ACSA or extended one generation study
Chronic/oncogenicity study
Additionally, several ﬁsh and invertebrate apical studies look at
the full life cycle and speciﬁcally at reproductive endpoints to test for
ecotoxicity of potential endocrine disruptors.
Two recent initiatives have dealt with deﬁning endocrine disrupt-
ing properties for the purposes of regulation: The ECETOC Workshop
on 25–26 June 2009 in Barcelona and the BfR Workshop on 11–13
November 2009 in Berlin (see Hirsch-Ernst presentation below). The
remainder of this presentation focused on the ECETOC proposal
(ECETOC, 2009). The ECETOC approach considers the Weybridge
deﬁnition of endocrine disruption and the principles of mode of
action, speciﬁcity and potency of the potential endocrine disrupter.
ECETOC further asks us to examine the weight of scientiﬁc evidence,
the human relevance and the assessment of risk of a pesticide with
potential endocrine disrupting properties.
The ECETOC approach is centred on a generic ﬂowchart: ﬁrst is a 5-
step approach to identify an endocrine disruptor from a mammalian
dataset and second is guidance on how to deal with speciﬁcity and
potency in order to discriminate chemicals of high concern, low
concern and no concern. Onlywhen a positive outcome in one ormore
endocrine sensitive endpoints is supported by mechanism of action(MoA) data (in vitro and in vivo studies) i.e., the sequence of the
biochemical and cellular events that underlies the adverse effect is
described and understood, then conclusive proof of endocrine
disruption can be considered as established.
Five potential scenarios are presented in Fig. 2 (A–E). In scenario A,
multi-endpoint studies show ‘no adverse health effects giving concern
for endocrine activity’; thus the conclusion is ‘No ED concern’. In
Scenario B, targeted endpoint studies indicate ‘endocrine activity
giving concern for endocrine toxicity’ but multi-endpoint studies
show ‘no adverse health effects…’. The conclusion is again ‘No ED
concern’.
In Scenario C there is ‘sufﬁcient evidence of endocrine disruption’
according to Weybridge. Here, multi-endpoint studies show ‘adverse
effects giving concern for endocrine toxicity’ and targeted endpoint
studies show ‘endocrine activity giving concern for endocrine
toxicity’. Thus, the adverse health effects seen in the multi-endpoint
study are supported by mechanistic evidence of an endocrine mode of
action.
In Scenario D, adverse effects are shown in apical studies but they
are not considered as sufﬁcient evidence of endocrine disruption
because the sequence of biochemical and cellular events to support an
ED-mediated mechanism cannot be deﬁned. In Scenario E, only
targeted endpoint studies are available and they show ‘no evidence of
endocrine activity’. The conclusion again is ‘no or insufﬁcient evidence
of endocrine disrupting mode of action’.
Substance(s) with results following Scenario C would be subject to
a further ﬂowchart where speciﬁcity, relevance and potency are
considered. If the adverse health effects are not speciﬁc to endocrine
activity then a risk assessment based on the non-endocrine endpoints
would be performed. If the adverse health effects are endocrine-
speciﬁc, then we ask if the mechanism of action is relevant to humans.
If it is not, we are back at the risk assessment based on non-endocrine
effects. If it is, we determine the potency of the endocrine disrupting
substance and consider that in the risk assessment.
The conclusion is that only substances showing adverse health
effects in apical studies supported by mechanistic evidence of the
endocrine mode of action should be called endocrine disrupters. This
approach considers health effects, mode of action, speciﬁcity, human
relevance and potency to come to an overall conclusion about the
endocrine disrupting potential of a chemical/pesticide.
Findings and Remaining Questions from the FP5 CREDO (Cluster
for Research on Endocrine Disruption) Investigations.
Prof. Andreas Kortenkamp, University of London, UK.
This talk began with a review of male reproductive disorders
which have seen a dramatic change in recent years. Hypospadias
(when the urethral opening is not at the tip of the penis) have
increased from approximately 20 to close to 40 per 10,000 births
between 1970 and 1995; testicular cancer from under 3 per 10,000 in
1973 to more than 5 per 10,000 in 2000; and sperm counts in Europe
have descended from over 150 million per milliliter in 1950 to 50
million per milliliter in 1990 (Sharpe and Skakkebaek, 2008). The
following question is posed: ‘Might increasing chemical exposures
play a role in these increases in reproductive disorders?’
Endocrine disrupting chemicals have been shown to cause
demasculinisation in animals by disrupting hormone action in foetal
life. An example is the pesticide vinclozolin which caused demascu-
linisation in rats exposed to 5 mg/kg body weight/day. However,
human vinclozolin exposure is estimated at only 0.005–0.01 mg/kg
body weight/day, a margin of safety of 200 to 1000 times. Before
accepting this level of exposure as safe, remember that vinclozolin is
not the only chemical humans are exposed to. Instead, there is a
veritable cocktail of daily chemical exposure including for example
vinclozolin and other pesticides, food packaging components, cos-
metics, dental and medical treatments, cleaning products, etc.
A developmental toxicity study looked at concurrent exposure to
three androgen receptor antagonists: vinclozolin, ﬂutamide and
Fig. 2. a) The ﬂowchart which is the basis of the ECETOC approach to identify a substance as having endocrine disrupting properties. b) The 2nd ECETOC ﬂowchart, to be applied to
those compounds identiﬁed as endocrine disrupters. Based on potency and speciﬁcity, this chart provides guidance for determining the appropriate level of concern.
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7 and postnatal day (PND) 16. Assessments of anogenital distance and
retained nipples in male offspring (two standard measures of
demasculinsation) showed dose additivity i.e., exposure to 10 mg/kg
of each of the three chemicals gave the same result as exposure to
30 mg/kg of one of them (Haas et al., 2007). Such additivity can be
viewed as ‘something from nothing’ – exposure to 10 mg/kg of any of
the three anti-androgens does not alter male physiology yetconcurrent exposure to this low level of all three together has
signiﬁcant effects. From this and other studies, the conclusion of EFSA
is that ‘cumulative effects from concurrent exposure to substances
which have a commonmode of action raise concerns and need further
consideration’.
The deﬁnition of a ‘common mode of action’ is not so simple nor
necessarily a valid criterion. Vinclozolin, prochloraz, ﬁnasteride and
DEHP are four anti-androgens which interfere with different steps of
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exposure to these four anti-androgens, following the method above,
signiﬁcantly altered nipple retention and anogenital distance (fem-
inising themale rats) and also decreased theweights of amale speciﬁc
muscle, the m. leviator ani and a male speciﬁc gland, the prostate
(Christiansen et al., 2009). Again, something from nothing as each
anti-androgen alone did not result in signiﬁcant change but four anti-
androgens, each at a ‘safe’ level, showed a dose additivity resulting in
altered gene expression and physiology – despite their different
mechanisms of action.
This presentation ﬁnished with a look at future challenges. How
shall chemicals be grouped together to test for cumulative effects?
Possibilities are mechanistic criteria such as ‘mode of action’ and/or
phenomenological criteria such as ‘adverse outcome’. With mode of
action, too narrow of a deﬁnition can exclude additive effects such as
those seen by Christiansen. With adverse outcome, a wide deﬁnition
such as androgen insufﬁciency syndrome would include such a large
number of chemicals that risk assessment studies would be daunting.
The challenge is to ﬁnd the way to perform these joint assessments
across diverse groups of chemicals.
Endocrine-Active Pesticides: Risks to Human Health.
Dr. HansMuilerman*, Pesticide ActionNetwork-Europe, Netherlands.
The presentation began with a review of overall pesticide use in
the European Union, showing an increase in pesticide application
between 1992 and 2002 – from under 200,000 to approximately
250,000 tonnes of active substance per year. The Netherlands and
Belgium lead the EU in kg of pesticide used per hectare with 12 and
11, respectively.
In 2003, a decrease to 200,000 tonnes of active pesticides was seen
in the EU, primarily due to a decrease in the use of fungicides, the
number one pesticide type in use. While this seems promising, the
presentation pointed out several continuing and inter-related
problems:
i) Pesticides that were withdrawn from use will have the
opportunity to be reintroduced, thus
ii) the overall pesticide package used in agriculture remains
largely unchanged.
iii) Mono-culture intensive agriculture is still the dominant style
(with its need for high pesticide use) and
iv) exposure to multiple pesticides through residues on food is on
the rise.
In the late 1990s, less than 15% of food samples contained multiple
pesticide residues and in 2007, 27% did. The number of different
pesticides found in a single sample has risen from 7 to 29 in the same
time period. A common reply is that these exposures do not exceed
the maximum residue level (MRL) set by authorities and thus pose no
threat to human health. However, a 2009 summary report from the
Standing Committee on the Food Chain and Animal Health states that
for 10 commonly used pesticides the MRL should be lowered because
at its current level the Acceptable Daily Intake (ADI) for these
pesticides may be exceeded (European Commission, 2009).
Determination of ADI and MRL is based on studies which can give
conﬂicting results. Often academic research ﬁnds that lower pesticide
concentrations have adverse effects while industry-funded research
shows that effects are present only at much higher concentrations. In
one example, the thyroid active pesticide mancozeb was shown in
academic research to cause multiple tumors at 0.4 mg/kg (Belpoggi et
al., 2002) while industry research reported no adverse effects at more
than 10 times that dose, 4.8 mg/kg. In an industry-friendly climate, as
in Brussels, industry-funded studies are favoured and consultation
with industry but not with academic scientists is routine. Mancozeb is
not the only pesticide for which different studies have found different
risks. A list of fungicides and herbicides shown in academic research
to have effects on thyroid function and on reproductive system was
presented.The speaker urged comparison of endocrines with asbestos.
Asbestos exposure will cause 250,000–400,000 cancers in Western
Europe in the next 35 years, all resulting from exposures that took
place over 10 years ago as asbestos was banned in 1998. Early
evidence that asbestos was dangerous was available 100 years earlier
but no action was taken. Are we making the same mistake with
endocrine-active pesticides?
Article 4 of the old EU Directive on pesticides was capable of
dealing with endocrine disrupters. It speciﬁed ‘no harmful effects…
directly or indirectly.’ and required a standard battery of toxicological
tests, including in vitro, in vivo, and 2-generation studies. Despite this,
possible endocrine effects of pesticides have not been acknowledged.
Some possible explanations include
i) a focus on getting the list of pesticides tested and avoiding
difﬁcult issues,
ii) a preference for industry-funded studies over academic studies
and
iii) a voting record based on commercial rather than health
concerns.
It seems that the new directive, with its direct language on
endocrine disrupters, is a breakthrough. However, there are still major
hurdles to overcome in which the mindset of traditional exposure
assays must be changed. For example, the development of the embryo
and foetus is regulated by hormones whose concentrations are in the
parts per billion or less! This makes low dose testing critical.
Furthermore, these very low concentrations are ﬁnely regulated by
a thermostat-like system and there are ‘windows of vulnerability’ or
‘critical periods’ which must be tested. Non-linear dose–response has
been shown for endocrine disrupters such as DES and makes the
‘threshold’ idea obsolete. DES has also shown that effects may occur
long after exposure has ended. Finally, the reality is that people are
exposed daily to a combination of potentially endocrine disrupting
chemicals and addressing such combinations should be the standard
in toxicology testing.
Several of the above points are illustrated by bisphenol A (BPA).
BPA has been shown to be present in human serum at concentrations
which are high enough to cause cell proliferation in in vivo tests, but
which are well below the No Observed Adverse Effect Level (NOAEL)
(Myers et al., 2009). BPA also illustrates the bias of industry testing:
hundreds of academic studies have found low dose BPA to have
deleterious effects while almost all industry-funded studies have
found BPA to be harmless. Similar contradictions between industry
and academic studies have occurred with soft drinks and tobacco.
The presentation concluded with a call to rely on unbiased
academic studies in setting policy. The process of peer review and
open literature publication allowing for easy replication and discus-
sion cannot be duplicated by industry-funded Good Laboratory
Practice (GLP) studies. Academic scientists who are actively publish-
ing in the endocrine disruption ﬁeld should be actively involved in
policy making.
Perception & Communication of Risks Associated with Food
Technology.
Prof. George Gaskell, London School of Economics, UK.
This presentation summarised the Eurobarometer 2006 study 238
on Food risk perception which was commissioned by the European
Food Safety Authority (EFSA) and DG Sanco. The aim of the study was
to ﬁnd out what risks Europeans associate with food, if there are
national differences in these perceptions and if qualitative and
quantitative approaches give different conclusions. The study in-
volved 27 countries with representative samples of 1000 from each
(except Cyprus and Malta). Closed questions asked for a rating of 1 to
4 (1= ‘not at all worried’ and 4= ‘very worried’ on 14 food risks and
the open question asked ‘What are all the things that come to your
mind when thinking about problems or risks associated with food?’
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linked to their Generalised Risk Sensitivity i.e., the more generally
worried a person is, the more likely they are to be worried about food.
Both measures showed strong country differences with the most Food
Risk Concern in Malta, Lithuania and Latvia (among the seven highest
in Generalised Risk Sensitivity) and the least in Finland, Austria and
Germany (among the eight lowest in Generalised Risk Sensitivity).
In the closed questions, the 14 food risks suggestedwere identiﬁed
by experts at EFSA and DG Sanco and fell into three categories as
follows:Health effects Adulteration Production & hygienePut on weight Pesticides Chemicals Lack of hygiene at home
Allergies Residues GM foods Lack of hygiene outside of homePollutants Additives Animal welfare
Bacteria New viruses
BSEThe number one food risk of concern to the public was pesticides in
fruits and vegetables, with an overall rating of 2.91 where 4= ‘very
worried’. The second concern was new viruses and the third residues
in meats. Of least concern was hygiene at home and allergies. By
country analyses showed the most concern about pesticides in Cyprus
and Greece, 3.45 and 3.4, respectively, and the least concern in the
Netherlands and Sweden, 2.42 and 2.6, respectively.
The open question on Food Riskwas posed before respondents saw
the 14 risks deﬁned by the experts. When asked to free associate, the
number one risk of concern was food poisoning, identiﬁed 16% of the
time, with pesticides, chemicals and toxic substances second,
identiﬁed 14% of the time. However, the open question showed that
the experts over represented concerns about adulteration and
underrepresented concerns about obesity and related disease.
This survey clearly shows that pesticides in food is potentially a
highly charged issue across Europe, though there are country
differences the concern is high throughout. In addition to public
concern, food regulators, NGOs and scientiﬁc bodies have all
expressed concern about pesticide residues in foods. REACH and the
rise in availability of organic food keeps focus on the potential risks of
pesticide contamination. Pre- and neonatal exposure to endocrine-
active pesticides has been linked to just about everything including
impaired neurological development of the foetus, breast cancer,
Parkinson's disease, Type 2 diabetes and even obesity. The conclusion
for risk communication is to be pro-active. It is necessary to inform the
public and to engage with science journalists. Transparency is critical.
Endocrine Disruptors and the EU Risk Assessment of Pesticides:
The Regulatory Perspective.
Dr. Manuela Tiramani*, EFSA, Italy.
This presentation began by identifying endocrine disruption as an
emerging public health and risk assessment issue, along with
developmental/neurotoxic agents and immunotoxicants. The speciﬁc
scientiﬁc criteria for the deﬁnition of ‘endocrine disrupting properties’
will be adopted by the European Commission in December 2013, and
until then interim measures will classify substances which are
identiﬁed as carcinogenic or toxic for reproduction as also having
endocrine disrupting properties. Additionally, speciﬁc reference to
endocrine disrupting properties is now made in the regulations on
Candidates for Substitution (Article 24) and Low-risk Active Sub-
stances, both of which speciﬁcally exclude compounds which are
considered to have endocrine disrupting properties.
Activities to identify endocrine active substances are underway:
ECETOC has prepared a ﬂow chart, identiﬁed standard and speciﬁc
tests and adopted a ﬁxed ED deﬁnition (presented earlier). BfR is
attempting to organise a consensus among specialists on how to deal
with low doses and how to speciﬁcally deﬁne ‘low dose’ and ‘adverse’
(presented next). In the US, the Environmental Protection Agency has
an endocrine disruptor screening programme to validate methods forestrogenic, androgenic and thyroid hormone-like substances. Despite
these initiatives, many open questions remain such as,
i) deﬁning ‘endocrine disrupter’ (ED),
ii) deciding if the focus should stay, as it has been, on reproductive
and thyroid hormones, or if other endocrine systems should
also be considered
iii) conﬁrming availability and appropriateness of testingmethods,
and
iv) joining ecotoxicology studies with mammalian studies.
A closer look at each point of the above points followed.
i) The International Programme on Chemical Safety and Wey-
bridge have proposed slightly different deﬁnitions of an
endocrine disrupter. It has been suggested by ECETOC to
adopt the Weybridge deﬁnition and this appears likely.
ii) Focus on the reproductive and thyroid systems may miss other
effects. Potentially all organs are susceptible to endocrine
disruption as any enzymatic chain can be altered by endocrines
and any dose may lead to short or long-term effects. Currently
there is no agreement on how to proceed here.
iii) Current testing methods do not identify all potential endpoints
(see point ii above) and often do not take into account potential
non-linear dose–response curves. An example is exposure to
the androgen antagonist hexachlorobenzene (HCB). In prostate
cancer cells, parts per billion concentration of HCB caused a
doubling of the androgenic response while at higher HCB
concentrations the androgenic response was repressed (Ralph
et al., 2003). In addition to potential low dose activity, EDs are
known to have effects that are dependent on species, age,
gender and timing of exposure. It is not clear if current studies
are tailored to test for this. Thus, several open questions remain
regarding current testing methods and these may result in a
failure to detect endocrine activity.
iv) A battery of tests proposed by the US EPA aims to combine in
vitro, in vivo and ecotoxicological approaches. Here, the Tier 1
tests include in vitro and in vivo screens in cells and organs of
several species. Tier 2 tests are multi-generation reproduction
and developmental tests again in several species. The Tier 2
tests should meet several criteria including
– Determine if effects are a primary or secondary disturbance
of endocrine function
– Establish exposure/concentration/timing and effects
relationships
– Be sensitive and speciﬁc
– Assess relevant endpoints
– Include life cycle of live-bearing and egg-laying species
– Include a dose range for full characterization of effects
– Be conducted in accordance with GLP
– Be validated.
Current experience in the EFSA Pesticide Risk Assessment Peer
Review (PRAPeR) show several current and pressing needs including
a clear deﬁnition of endocrine disruption and guidelines to reduce
uncertainties, scientiﬁc and practical tools, and harmonisation in
interim measures. Research is needed to understand the basic science
and mechanisms of action, and to develop measurement methods
and risk assessment models. Screening and testing methodologies
have to be developed to identify potential endocrine disrupters and to
determine adverse effects and dose–response curves and to assess
risk, taking into account the requirements of the current legislation.
The presentation concluded with a review of the next steps to be
taken in order to reach a consensus on how to regulate endocrine-
active pesticides. First the development and validation of appropriate
screens and tests, to be followed by development of procedures and
policies and ﬁnally development of standard evaluations and risk
assessment guidelines. This is a big order, but progress has begun. At
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accepted two assays and validated a third. The Hershberger assay
(Test Guideline 441) and the Human Estrogen Receptor Transcription
Assay (Test Guideline 455) were adopted as standard tests and the
Repeat Dose 28-day Oral Toxicity (Test Guideline 407) was updated
and validated, although here some further ﬁne tuning may be
necessary. Finally an examination of validated Quantitative Struc-
ture-Activity Relationships could allow an automated look at
numerous compounds without the use of animal studies.
Decision Criteria in Human Health Risk Assessment for ED
Substances.
Dr. Karen Hirsch-Ernst, BfR, Germany.
This talk was a summary of the meeting Establishment of
assessment and decision criteria in human health risk assessment for
substances with endocrine disrupting properties under the EU plant
protection product regulation, hosted by the German Federal Institute
for Risk Assessment (BfR) in Berlin from 11 to 13 November 2009. This
was a preliminary report, reﬂecting the discussion and part of the
results of the BfR workshop, but not necessarily detailing the opinion
of all participants or of the institutions they work for.
Participants at the BfR workshop provided recommendations for
the criteria that should be used for regulatory assessment of potential
endocrine disrupting compounds. A decision tree provided by BfR at
the start of the workshop was considered useful and was updated by
workshop participants. The tree has 4 basic steps for reaching a
decision onwhether a compound should be regulated as an endocrine
disrupter:
1) consider all available toxicological data,
2) look for evidence of an endocrine mechanism of action,
3) look for relevance of the mechanism to humans and
4) determine human exposure to decide if regulation is necessary.
The workshop participants suggested that in the consideration of
toxicological data, substances that are known to cause cancer,
developmental or reproductive defects not be excluded from
endocrine testing as such substances may also be endocrine
disrupters. Additionally, the hazards identiﬁed in step 1 that justify
moving to the analysis of mechanism in step 2, include cancer and
speciﬁc target organ toxicity – thus not only effects on the endocrine
system itself, but also effects on target organs.
The updated decision tree then considered mechanism of action of
the chemical in question. Here any adverse effects potentially related
to endocrine disruption would have to be analysed separately looking
independently at the mechanism for each. Since hormones are
involved in the regulation of virtually all physiological processes, it
is critical to identify what are ‘adverse’ hormonal effects. The
workshop participants agreed on theWHO/IPCS deﬁnition of adverse:
‘A change in morphology, physiology, growth, reproduction, devel-
opment or lifespan of an organism which results in impairment of
functional capacity or impairment of capacity to compensate for
additional stress or increased susceptibility to the harmful effects of
other environmental inﬂuences.’
Here, additional studies may be required to show adversity, but
the default assumption would be that the mechanism is endocrine
unless data clearly show that it is not in which case one could leave
the decision tree here.
In step 3 of the decision tree, relevance to humans is considered.
Here, workshop participants felt that the default decision is that
animal studies are relevant to humans. Only if a mechanism of toxicity
in animals is clearly not relevant to humans could the decision tree be
left at this step.
Finally the amount of human exposure should be considered. As
stated in the EC regulation (see Introduction, page1) if exposure is‘negligible’ a compound need not be regulated. Currently, exposure to
less than 0.01 mg/kg food is considered a negligible amount of any
substance. Here, workshop participants pointed out the need for a
science-based deﬁnition of negligible as opposed to a default value.
The deﬁnition should consider the potency of a substance as well as its
potential for low dose effects. Thus different substances would have
different ‘negligible’ amounts and no single default value would be
used.
Discussions at the BfR workshop were lively and differences of
opinion were expressed on some critical points. Controversy was high
concerning the idea of speciﬁcity, with some participants arguing that
if a substance causes a general toxicity than any effects that it may
have on endocrine systems are likely secondary i.e., not speciﬁc, and
should therefore not be considered endocrine disruptive. Others felt
strongly that an effect should not be considered irrelevant purely on
the basis of it being secondary and argued that the central issue of
endocrine disruption is mechanism, i.e., binding to a receptor, and not
order of effect. This discussion could not be resolved and ‘speciﬁcity’
was not included in the proposed decision tree for identifying
endocrine disruptive substances.
Another controversial discussion concerned potential low dose
effects. Here some participants felt strongly that robust evidence,
including reproducibility of effects, was lacking. Others pointed out
that routinely testing more dose levels would increase the number of
animals used in studies when there are no concrete decisions yet on
which endpoints to test or which doses to test them at and thus no
uniformity or reproducibility is possible. Still others felt that
potentially important endocrine effects might be missed if current
testing strategies continue unchanged and that there is enough
preliminary evidence of low dose and non-linear dose responses that
we must not ignore this issue. This discussion was resolved with the
group suggesting that the low dose issue move forward with further
research, critical literature reviews and further workshops.
The presentation summed up that at the BfR meeting, it was
strongly agreed that the criteria laid down in the interim regulation,
as stated in the Introduction, page 1, are not sufﬁcient and that speciﬁc
scientiﬁc criteria should be developed as soon as possible. To achieve
this, it was agreed by the meeting participants that further steps,
including research to gather missing data, meetings with the public,
regulators and other stakeholders to discuss the latest ﬁndings,
publication of research and regulatory consequences and further
workshops to reﬁne testing guidelines and study designs should all
continue.
Pesticide Residues: Factors Determining Potential Endocrine
Toxicity.
Dr. Cliff Elcombe*, Biomedical Research Institute, University of
Dundee and CXR Biosciences, Scotland.
This presentation covered which pesticides are found on common
fruits and vegetables and showed how the standard exposure–dose–
response paradigm for carcinogens and toxicants can be applied to
endocrine active pesticides as well. The incidence of pesticide residues
in produce shows that, while most produce does contain pesticide
residues, and most contains residues of multiple pesticides, the
amount of these residues rarely exceeds the Maximum Residue Level
(MRL) set by government authorities. Recently, four of 20 different
foods tested contained pesticide residues that exceeded the MRL.
The standard exposure–dose–response paradigm for carcinogens
and toxicants is shown in Fig. 3. At each step in this schematic, many
variables are possible. For exposure, it may occur by inhalation, by
skin contact or orally. In the case of pesticides (with the exception of
pesticide workers who would be subject to inhalation and skin
contact) exposure for the majority of the population is oral. Here we
must consider the amount of pesticide one is exposed to, the
frequency of exposure and the fact of simultaneous multiple
exposures. There may be interactions among different pesticides
that alter their activity.
Toxic response 
Tissue dose 






Fig. 3. Standard summary ﬂowchart of the steps between exposure to a potential
toxicant and its toxic effect on the body. Each stepmay be inﬂuenced bymany variables.
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resulting in a certain blood concentration of pesticide. Again there are
multiple variables here. Absorption may occur completely, somewhat
or not at all. It may be inﬂuenced by numerous individual
characteristics including sex and other genetically determined factors,
age, and health/nutritional status for example. Blood concentration
and availability may also be changed by blood binding proteins which
can bind and therefore make unavailable different hormones and
hormone-like chemicals.
From the blood, different tissues will be subject to speciﬁc tissue
doses of the toxic moiety one has been exposed to. The long term
tissue dose will vary depending on whether the pesticide is one that
accumulates or one that is excreted. If it is excreted, the half life of the
particular pesticide will determine just how quickly its concentration
declines. The tissue dose will also vary from the exposure dose if the
toxin has been metabolically activated or inactivated, most likely by
the liver but also possible in the tissue itself. A further complication
is that pesticides may inhibit the liver's cytochrome P450 system,
an enzyme system that metabolises toxins, including pesticides
themselves. The pesticide buprimate for example will inhibit no less
than 5 cytochrome P450s and a range of other pesticides inhibit
the cytochrome P450 1A2 with Ki (concentration at which P450
activity is one half) ranging from 0.34 to 12.7 micromolar. Finally, the
metabolites formed by liver or tissue systems may be more or less
toxic than the original pesticide.
Next on the exposure–dose–response paradigm is toxic moiety-
target interactions. These interactions include for example receptor
binding followed by transcriptional activation or inactivation, cofactor
depletion, direct gene mutation, enzyme activation or inhibition. Of
these, a common interaction is receptor binding (see Fig. 1, Gustaffson
presentation) in which a speciﬁc ‘lock and key’ interaction occurs
between the toxic moiety and, in the case of steroid hormonemimics, a
nuclear receptor. Receptor binding is regulated by the afﬁnity between
ligand(s) and receptors and by the kinetics of ligand receptor in-
teractions. Ligands for (nuclear) receptors come in several types
including i) agonists, which bind and activate the receptor, ii)
antagonists which bind but do not activate the receptor (and thus
prevent binding of an agonist), iii) mixed agonists/antagonists, which
bind and activate or not depending on other factors and iv) inverse
agonists, which bind preferentially when the receptor is ‘inactive’
therefore reducing constitutive activity (low level of receptor activity
present in the absence of ligand). The complexity of nuclear hormone
receptors' regulation of gene transcription can not be overstated. There
is amultiplicity of controls including for example, heterodimerisation of
receptors, coactivator availability, and multiple feedback systems, etc.
The ﬁnal step in the exposure–dose–response paradigm is the toxic
response. There are many possible types of toxicity including acute,subacute and chronic insults. Among acute one would list necrosis,
apoptosis and malformation; in subacute organ growth for example
and an example of a chronic toxicity is cancer (Elcombe et al., 2002).
The presentation concluded that the safety evaluation of all
pesticides, whether or not suspected of endocrine activity, should
be based on an understanding of both mechanism of action and
exposure levels.
4. Breakout groups
Attendees were divided into four groups by the Workshop
Organising Committee (OC), with each group containing representa-
tives from for-proﬁt (industry) and non-proﬁts (NGO, government
and academia).
Questions prepared by the OC were assigned to each group and
instructions were to prepare a short presentation on the group's
position indicating whether unanimity, consensus, limited agree-
ment, or no agreement was reached. These four termswere deﬁned by
the Chairman of the Workshop (Dr. Neil Carmichael of ECETOC) in his
introductory presentation as follows:
Unanimity No signiﬁcant disagreement
Consensus General agreement with possibility of some detail
reservations
Limited agreement General agreement butwith signiﬁcant reservations
No agreement No agreement
Question 1:
Are levels of exposure just as important as potency in discussions
on endocrine-active pesticides? and Should both be given equal
weight in regulatory decisions?
Here, unanimity was reached for ‘yes’ to both questions. The group
agreed that both parameters, hazard and exposure, are needed for
informed discussion. The group further stated that risk assessment
principles must be used and that risk assessment should be
transparent and open-minded so that trust and respect among the
various stakeholders could be maintained. A discussion on how to
generate trust and the importance of trust and respect between
industry and academia followed. It was noted that dialog is impossible
in a situation of distrust and accusation.
A proposition for deﬁning different classes of endocrine disrupters
depending on their level of hazard was put forth. Three categories
were suggested:
i) substance should be banned
ii) risk assessment needed
iii) no evidence of danger
It was clearly stated in the group presentation that adequate
evidence for the decision scheme for such a classiﬁcation must be
available. A suggestion in the discussion was that scientists actively
publishing in the ﬁeld agree on the appropriate tests and that a ‘ring
test’ of case studies be performed i.e., several laboratories perform the
proposed tests and compare results. It was noted that the currently
used default value of 0.01 mg/kg as an acceptable exposure to all
pesticides was not scientiﬁcally based and should be discarded.
The ﬁnal statement of the group was a call for a Workshop on low
dose effects with a focus on being open-minded. All stakeholders
should participate and study designs should be openly discussed,
clariﬁed and validated.
Question 2:
Is endocrine disruption a mechanism essentially different from
other toxicological mechanisms? and Should it therefore be regulated
using different criteria?
Here there was no agreement on an answer for either question.
The group speciﬁed that they could not agree ‘yes’, endocrine
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nisms nor could they agree ‘no’, endocrine disruption is not essentially
different from other toxicological mechanisms. The group suggested
that the question may be unanswerable because ‘endocrine disrup-
tion’ is too broad of a term. Perhaps a more speciﬁc question could
address the same or a similar issue?
Regarding the ﬁrst part of the question, the group suggested that
endocrine disruption may be too broad of a term because, unlike e.g.,
carcinogenesis, there is no clear endpoint for endocrine disruption. In
order to have effective regulation, the group stated that there must be
clarity and agreement on assay(s) with clear endpoints, i.e., clearly
deﬁned and measurable effects of endocrine disruption, this lack was
identiﬁed as the primary scientiﬁc difﬁculty. It also must be
determined if threshold values exist.
Therewas limitedagreement in the group regardingdifferent classes
of endocrine disrupters based on the associated level of concern. The
three level classiﬁcation scheme suggested by group one was discussed
as a possible starting point. The group pointed out that while some
endocrine disrupters do have serious toxicological consequences, that
does not necessarilymean they should be treated differently fromother
toxins which may also have serious toxicological consequences.
The group did agree that ‘hazard and risk assessment [for
endocrine disrupters] should be based on scientiﬁc criteria’.
Question 3:
Are the current testing strategies for endocrine-active pesticides
adequate? and
Where are the greatest needs for further test development?
Here, the group reached consensus on the ﬁrst part of the question,
current testing strategies are considered adequate with only small
reservations. However, the group identiﬁed several major areas as
needing further test development.
Current testing strategies include 1) carcinogenicity testing and
2) two generation testing. Carcinogenicity tests are lifetime exposures
looking at multiple endpoints. They are generally performed in two
species and use three doses separated by a factor of ten. These tests
were considered adequate by the group. Two generation tests involve
a ten week treatment of the F0 generation, mating of F0, exposure of
F1 through their sacriﬁce at four months of age (after mating and
weaning of pups), and exposure of F2 through their sacriﬁce at
21 days of age (after weaning). Here there were serious reservations
about the accuracy of this testing scheme. It was noted that exposure
through fourmonths of age is not ‘lifetime exposure’. Effects that don't
appear until middle and/or old age would likely be missed. Such
delayed effects are one of the hallmarks of endocrine disrupters.
Additionally, multiparous females are never tested. Effects related to
multiple pregnancies (in themother or in the offspring) would also be
missed by this testing scheme.
The greatest needs for test development were identiﬁed as 1) low
doses and 2) subpopulations. Regarding testing of low doses, it was
noted that different endpoints have different sensitivities. An assay
used in low dose testing might show no effect, while another assay,
testing a different endpoint, might very well show an effect at the
same dose. The group agreed that any in vitro effects of low doses
must be followed by in vivo testing. An unanswered question closed
this area, ‘what are the regulatory consequences of low dose effects?’
Testing of speciﬁc subpopulations (of perhaps differing sensitiv-
ities) was another area where the group suggested test development.
Speciﬁc populations would include but not be limited to
i) those exposed to other knownor suspected endocrine disrupters
(e.g., concurrent exposure to speciﬁc pharmaceuticals),
ii) those following different diets (e.g., vegetarian, high/low fat,
Asian or Mediterranean),
iii) different ages (particularly elderly as discussed above) and
iv) gender (simple male/female differences but also related to age
e.g., reproductive senescence).Animal models used for routine in vivo testing were discussed and
it was agreed that while the rat is viewed as the standard, depending
on the endpoint this may not be appropriate. The rat, for example, is
not the best model of human birth; at parturition, the seldom-used
guinea pig has a hormonal proﬁle much more like that of the human.
The group agreed that while an increase in animal studies is not
desirable, there is a need for test development in other than the
typical species so that, depending on the endpoint, the model that is
most like the human can be used. It was agreed that this development
was needed, but not to put this on the list of ‘greatest needs’.
Testing of mixtures was discussed but agreement could not be
reached on whether or not to place this on the list of ‘greatest needs
for further test development’. It was agreed by the group that testing
of mixtures is an important issue, but a tremendous issue and
extremely hard to tackle. It was suggested that company testing of
formulations might be a good starting place. It was also noted that the
potential risk of exposure to mixtures does not require different tests
but rather use of existing (and suggested) tests but applied mixtures
rather than single compounds.
Question 4:
Are the perceived risks associated with dietary exposure to
endocrine-active pesticides proportional to the actual risks? and Is
the effort currently dedicated to this subject proportional to the real
health risk?
This group reached ‘consensus on the ﬁrst question but ‘no
agreement’ on question two’. For question one, are perceived risks
proportional to actual risks, the group pointed out that this depends
on who you ask. We need the perspective of true knowledge to have
the answer to this question –we don't know the ‘actual risks’. Despite
these questions, the group agreed that perceived risks are higher than
actual risks. They pointed out that current EU regulations give
disproportional attention to endocrine disrupters when there is no
scientiﬁc basis for treating endocrine disruption differently from any
other toxicological mechanism and no proof of causality for any
currently registered pesticide and an endocrine-related effect.
For the second question, the group noted that there are different
efforts currently dedicated to endocrine disruption: a scientiﬁc effort,
a regulatory effort and a risk assessment effort. The scientiﬁc effort
was viewed as proportional to the real health risk as there is a need to
elucidate the real risk of endocrine disruption and the risk from
endocrine-active pesticides versus the risk from other sources of
endocrine disrupters. The regulatory effort applied to endocrine
disrupter exposure was viewed as much greater than the real health
risk. It was noted that other health problems, i.e., obesity, receive
much less regulatory attention despite the general acknowledgement
of severe health risks. In risk communication, the effort was again
seen as greater than the risk with the comment that detection and
contamination are not the same. With current methodologies,
detection of endocrine-active pesticide residues may be possible
even for minute quantities, this does not necessarily imply that the
food is contaminated and unsafe.
A ﬁnal point made by this group concerned the need for integrated
risk–beneﬁt analysis when considering endocrine disrupting proper-
ties of pesticides. The beneﬁts of pesticide use in health e.g.,
combating mycotoxins and supply e.g., food security and food prices,
must be considered against the risks of exposure to endocrine-active
substances in pesticide products.
5. Discussion and conclusions
At this workshop, endocrine experts from different sectors
presented and discussed some of the most recent scientiﬁc ﬁndings,
possible frameworks for interpretation and potential regulatory
outcomes of dietary exposure to endocrine active pesticides. Diverse
opinions were presented by a broad and opposing range of
stakeholders and the workshop was considered scientiﬁcally sound.
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and government regulators allowed accusations to bemade and for the
accused to defend themselves. The progresswas the acceptance thatwe
must work together to ﬁnd the appropriate solutions. There was a
general consensus for example, that more research and more focused
research is necessary in order to make scientiﬁcally-based decisions on
the regulation of endocrine-active compounds.
What regulators should dowhile that research is in progress was an
area of dissension. Therewas a clear conﬂict between the ‘precautionary
approach’ and the ‘pragmatic approach’, with the former supporting a
ban on suspected endocrine disrupting pesticides until there are studies
showing no adverse effects and the latter suggesting that all currently
approved compounds have already been rigorously tested and not
enough evidence found to deny their approval. Ultimately the decision
to go pragmatic or precautionary must be made before all the evidence
is in, but we should be careful of those who will continue to argue long
past the point of reason that there is not enough evidence – look at the
cigarette companies claiming for decades that there was no conclusive
evidence linking smoking and lung cancer.
The other area of distinct disagreement concerned exposure to
mixtures of endocrine active compounds. On the one side was a group
calling for ‘reality testing’ – humans and other non-target organisms
are exposed to a mixture of endocrine active compounds not to a
single compound a time. Thus current tests don't give a true picture of
the risks we face and, given the evidence of additive and synergistic
effects, we cannot afford to ignore this reality. Others, however,
argued that adequate mixture testing is almost impossible because of
the inﬁnite number of compounds and concentrations possible and
that we should focus on single compounds.
There was disagreement on the relative value of academic versus
industry-funded studies, with arguments that only open access,
academic research be used when making regulatory decisions.
Based on conversations during and after the workshop, the
workshop goals of i) stimulating an informed debate on effects of
exposure to endocrine-active pesticides and ii) stimulating policy
making based on scientiﬁc evidence were achieved. It was largely
agreed that this workshop contributed to a debate that should
continue, and that contentious issues related to endocrine disrupting
effects, e.g., low dose effects, mixtures and worldwide vs. European
regulatory efforts, need further examination.
To address this, the SAFE consortium is organizing a second
workshop on endocrines, with a focus on low dose exposures and
non-monotonic dose–response curves in March 2011, and a report of
that workshop will follow.
Appendix
The endocrine system is made up of glands located throughout the
body, and the chemical substances called hormones which these
glands produce and secrete into the blood. The major glands of the
human endocrine system are (from top to bottom): Pineal, Hypo-
thalamus, Pituitary, Thyroid, Parathyroid, Thymus, Adrenal, Pancreas
and Gonads (ovaries or testes). Some organs whose primary function
lies within another system of the body may also act as endocrine
glands; examples are the kidneys, the stomach and the small
intestine. Recently, synthetic substances which act like hormones
have been identiﬁed – examples include pesticides, industrial
compounds and pharmaceuticals; additionally, naturally occurring
plant compounds may have hormone-like activity as for example
some components of soy beans.
The chemical nature of hormones is varied, they may be amines or
peptides or proteins or lipids or combinations of these, but all hormones
act by binding to a receptor molecule, which is a protein located either
on the cell membrane or in the cytoplasm of a target cell. A general rule
is that lipid hormones bind to their hormone receptor in the nucleus
while protein hormones bind to theirs on the cell membrane. Thechemical nature of both hormones and their receptors has been well
conserved throughout evolution and the sameor similarmolecules have
the same or similar hormonal functions in different animal species.
Synthetic hormone-like compounds tend to mimic steroid hormones;
primarily estrogen, testosterone and thyroid hormone, and these
hormone mimics can bind to the natural hormone receptors. Since the
target cells for a hormone (i.e., cells with a receptor for that hormone)
may be found throughout the body (e.g., target cells for estrogen are
located in the uterus but also in the mammary glands, the brain, the
muscles, bone, and other locations), both hormones and hormone
mimics may have wide ranging and diverse effects.
An important part of the deﬁnition of hormones is that they are
active in very small amounts; hormone concentrations are generally
measured in the range of nano or picograms, i.e., billionths or
trillionths of a gram, per milliliter. These miniscule amounts however
are capable of causing large changes in body function. This can be
easily understood when one considers the mechanisms of hormone
action. Most lipid, or more speciﬁcally steroid hormones, enter the
nucleus and bind to receptors which then complex with DNA – thus
these hormones directly alter gene expression which can of course
have very wide ranging and even permanent effects on the organism.
Hormones that bind to the cell membrane act via a ‘cascade’ in which
a sequence of intermediate molecules are produced, with each one
causing the activation of thousands or hundreds of thousands of
molecules in the next step – thus these hormones have results which
are orders of magnitude greater than their own concentrations.
Exposure to very low levels of hormone-like substances may have
large effects because these hormone mimics are magniﬁed via the
same mechanisms that serve to magnify the very low levels of
naturally occurring hormones.
Formany hormones, concentration and activity vary throughout the
organism's lifespan. The sex steroid hormones are present in utero,
dormant throughout childhood, very active in adolescence, continu-
ously active throughout the reproductive years and minimal in old age.
Thus hormoneeffectsmay occur only during a very speciﬁc timeof life, a
‘critical period’ when a speciﬁc amount of hormone is necessary for a
speciﬁc effect. Additionally, the hormone effect may be ‘organisational’
or the basis of future events which can only take place if that hormonal
effect has been successfully completed. For example, for a male dog to
urinate in a ‘male’ position testosterone is not required at that moment,
rather the dog must have been exposed to appropriate testosterone
during in utero development. An adult female dog given testosterone
will not urinate like a male, but a female dog exposed to testosterone
while in utero, even for a very brief time, will urinate in the male
position when an adult even if she is never again exposed to
testosterone. Exposure to hormone mimics, therefore, may have effects
ranging from none to lifelong depending both on the age of the
organism at exposure and on the quantity of the exposure. This fact has
caused a lot of concern about the exposure of pregnant women and
young children to endocrine active substances in our environment.
Hormone mimics may be agonists, causing the same effect as the
natural hormone and thus a hyper-hormonal condition, or they may
be antagonists, fully or partially blocking the effect of the natural
hormone and causing a hypo-hormonal condition, or they may be an
agonist at one concentration and an antagonist at another. While it is
generally agreed that hormonemimics have had harmful effects in the
wild, the effects on humans are still a matter of scientiﬁc debate.
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